News Image

INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech

By Mill Chart

Last update: May 30, 2025

INCYTE CORP (NASDAQ:INCY) stands out as an intriguing candidate for value investors, according to our fundamental screening criteria. The biopharmaceutical company demonstrates a strong valuation profile while maintaining solid profitability and financial health. Below, we examine why INCY may be worth a closer look.

INCYTE CORP stock chart

Valuation

INCY scores an 8 out of 10 in valuation, indicating it is attractively priced relative to its fundamentals:

  • Forward P/E of 9.46 – Significantly lower than both the industry average (57.58) and the S&P 500 (22.13).
  • Price/Free Cash Flow – Cheaper than 93.75% of its biotechnology peers.
  • Enterprise Value/EBITDA – More affordable than 93.39% of industry competitors.

Despite a high trailing P/E (35.89), the forward earnings multiple suggests the market may be undervaluing INCY’s future earnings potential.

Financial Health

With a health rating of 7, INCY maintains a stable balance sheet:

  • Low Debt – A Debt/Equity ratio of 0.01 indicates minimal reliance on borrowing.
  • Strong Solvency – A Debt-to-FCF ratio of 0.12 means the company could repay its debt quickly.
  • Liquidity – Current and Quick Ratios above 2 confirm sufficient short-term financial flexibility.

Profitability

INCY earns a profitability score of 7, supported by:

  • High Margins – Gross Margin of 93.19% outperforms 93.75% of industry peers.
  • Strong ROIC – At 4.67%, it exceeds 92.86% of competitors.
  • Operating Efficiency – An Operating Margin of 5.39% ranks in the top 7% of the sector.

Growth

While growth is more moderate (rating of 4), there are positive signs:

  • Revenue Growth – Increased 17.13% over the past year, with a 5-year average of 14.46%.
  • Future EPS Growth – Expected to rise by 25.93% annually, signaling improving profitability.

Our Decent Value Stocks screener lists more stocks with similar characteristics. For a deeper dive, review the full fundamental report on INCY.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.

INCYTE CORP

NASDAQ:INCY (5/30/2025, 8:05:09 PM)

After market: 65.06 0 (0%)

65.06

-0.98 (-1.48%)



Find more stocks in the Stock Screener

INCY Latest News and Analysis

ChartMill News Image2 days ago - ChartmillINCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech

INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term investors.

ChartMill News Image12 days ago - ChartmillWhat's going on in today's session: S&P500 movers

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.

Mentions: NEM REGN HUM FDX ...

Follow ChartMill for more